|
Synonyms: Ebglyss® | MILR1444A | RG3637 | TNX-650
lebrikizumab is an approved drug (EMA (2023))
Compound class:
Antibody
Comment: Lebrikizumab is a an anti-IL-13 monoclonal antibody.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
| References |
|
1. Adams B.
Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease. Accessed on 09/02/2018. Modified on 09/02/2018. fiercebiotech.com, https://www.fiercebiotech.com/biotech/sanofi-ditches-il4-il13-antibody-drug-lung-scarring-disease |
|
2. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z et al.. (2011)
Lebrikizumab treatment in adults with asthma. N Engl J Med, 365 (12): 1088-98. [PMID:21812663] |
|
3. Fung SC, Moyle M. (2010)
Treatment of Interleukin13 dependent neoplastic disorders. Patent number: US7674459. Assignee: Genentech, Inc.. Priority date: 23/12/2003. Publication date: 09/03/2010. |
|
4. Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG. (2014)
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy, 44 (1): 38-46. [PMID:24131304] |
|
5. Ultsch M, Bevers J, Nakamura G, Vandlen R, Kelley RF, Wu LC, Eigenbrot C. (2013)
Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol, 425 (8): 1330-9. [PMID:23357170] |
|
6. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. (1998)
Interleukin-13: central mediator of allergic asthma. Science, 282 (5397): 2258-61. [PMID:9856949] |
